Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

Efficacy Comparison:
A recent clinical trial, SURMOUNT-5, found that Eli Lilly's Zepbound (tirzepatide) led to a 20.2% average weight loss compared to 13.7% with Novo Nordisk's Wegovy (semaglutide) after 72 weeks23.

Weight Loss Figures:
Participants on Zepbound lost an average of 50.3 pounds, while those on Wegovy lost 33.1 pounds23.

Mechanism of Action:
Zepbound works by targeting both GIP and GLP-1 receptors, whereas Wegovy only targets GLP-1 receptors, which may explain its superior efficacy12.

Clinical Significance:
The study suggests that dual mechanisms of action, like those in Zepbound, can lead to greater weight loss compared to single-action drugs like Wegovy1.

Safety Profile:
The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously reported trials, with gastrointestinal-related adverse events being the most common2.

Regulatory Status:
Both Zepbound and Wegovy are FDA-approved for weight loss, while Mounjaro (also tirzepatide) and Ozempic (semaglutide) are approved for Type 2 diabetes but sometimes prescribed off-label for weight loss12.

Sources:

1. https://abcnews.go.com/GMA/Wellness/zepbound-leads-weight-loss-wegovy-new-study-finds/story?id=116427373

2. https://www.prnewswire.com/news-releases/lillys-zepbound-tirzepatide-superior-to-wegovy-semaglutide-in-head-to-head-trial-showing-an-average-weight-loss-of-20-2-vs-13-7-302322351.html

3. https://fortune.com/well/article/zepbound-vs-wegovy-weight-loss-clinical-trial/